Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 277

Similar articles for PubMed (Select 21085635)

1.

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E.

PLoS One. 2010 Nov 11;5(11):e13540. doi: 10.1371/journal.pone.0013540.

2.

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN.

AIDS. 2012 Feb 20;26(4):F1-12. doi: 10.1097/QAD.0b013e32834f33e8.

PMID:
22156965
3.

HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.

Zaccarelli-Filho CA, Ono E, Machado DM, Brunialti M, Succi RC, Salomão R, Kallás EG, de Moraes-Pinto MI.

Cytometry B Clin Cytom. 2007 Jan 15;72(1):14-21.

4.

HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.

Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B.

Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.

5.

HCV coinfection does not alter the frequency of regulatory T cells or CD8+ T cell immune activation in chronically infected HIV+ Chinese subjects.

Zhuang Y, Wei X, Li Y, Zhao K, Zhang J, Kang W, Sun Y.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1044-51. doi: 10.1089/AID.2011.0318. Epub 2012 Mar 2.

PMID:
22214236
6.

Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.

Zhang ZN, Shang H, Jiang YJ, Liu J, Dai D, Diao YY, Geng WQ, Jin X, Wang YN.

Chin Med J (Engl). 2006 Dec 5;119(23):1966-71.

PMID:
17199940
7.

Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals.

Lisziewicz J, Bakare N, Calarota SA, Bánhegyi D, Szlávik J, Ujhelyi E, Tőke ER, Molnár L, Lisziewicz Z, Autran B, Lori F.

PLoS One. 2012;7(5):e35416. doi: 10.1371/journal.pone.0035416. Epub 2012 May 9.

8.

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.

Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B.

Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.

9.

Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.

Benito JM, López M, Lozano S, Ballesteros C, Martinez P, González-Lahoz J, Soriano V.

J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):373-81.

PMID:
15764953
10.

Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.

Beran O, Holub M, Spála J, Kalanin J, Stanková M.

Acta Virol. 2003;47(2):121-4.

PMID:
14524479
11.

A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.

Lichtenstein KA, Armon C, Nagabhushanam V, Efaw BJ, Frazer-Abel A, Hiserote ME, Alam R.

Antivir Ther. 2012;17(7):1301-9. doi: 10.3851/IMP2350. Epub 2012 Sep 5.

PMID:
22948290
12.

CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination.

Jost S, Tomezsko PJ, Rands K, Toth I, Lichterfeld M, Gandhi RT, Altfeld M.

J Virol. 2014 Aug;88(15):8349-54. doi: 10.1128/JVI.00924-14. Epub 2014 May 14.

13.

Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study.

Johnston AM, Valentine ME, Ottinger J, Baydo R, Gryszowka V, Vavro C, Weinhold K, St Clair M, McKinney RE.

Pediatr Infect Dis J. 2001 Oct;20(10):941-6.

PMID:
11642627
14.
15.

New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.

Gahery H, Daniel N, Charmeteau B, Ourth L, Jackson A, Andrieu M, Choppin J, Salmon D, Pialoux G, Guillet JG.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):684-94.

PMID:
16831093
17.

Immune restoration under HAART in patients chronically infected with HIV-1: diversity of T, B, and NK immune responses.

Le Guillou-Guillemette H, Renier G, Vielle B, Abgueguen P, Chennebault JM, Lunel F, Payan C.

Viral Immunol. 2006 Summer;19(2):267-76.

PMID:
16817769
18.

Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection.

Pettersen FO, Taskén K, Kvale D.

Clin Exp Immunol. 2010 Aug;161(2):315-23. doi: 10.1111/j.1365-2249.2010.04179.x. Epub 2010 May 10.

19.

Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.

Piriou E, Jansen CA, van Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D.

J Immunol. 2005 Aug 1;175(3):2010-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk